Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective case series, baricitinib showed effectiveness in treating severe alopecia areata but had mixed results for psoriasis and was not optimal for psoriatic arthritis in patients with coexisting conditions, suggesting further studies are needed.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This article discusses the history and understanding of Tay syndrome, recognizing it as a distinct condition related to ichthyotic erythroderma, mental retardation, and brittle hair but reports no new clinical results.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This study reports that baricitinib was effective and well-tolerated over 52 weeks for severe alopecia areata, with significant improvements in disease severity and no serious adverse events.

This review compiles existing research on ischemia-modified albumin (IMA) as a biomarker for myocardial ischemia, highlighting current gaps in understanding its formation and detection, with no new clinical results reported.

In this study, the researchers reported that baricitinib improved hair loss in a real-world setting for Japanese adults with alopecia areata, with a 64.7% success rate at 60 weeks, though prolonged episodes reduced efficacy. Common side effects were acne and mildly decreased renal function.

In this study, baricitinib was well tolerated and led to clinical improvement in patients with treatment-resistant alopecia areata in a real-world clinical setting, suggesting it may be a potential treatment option.

In this phase 3 trial analysis, baricitinib improved scalp hair growth in adults with severe alopecia areata, with a faster and higher response in those receiving 4 mg compared to 2 mg, but response varied with severity at baseline and continued through week 52.

This case report highlights that Baricitinib led to significant hair regrowth and resolution of atopic dermatitis symptoms in a 22-year-old female with coexisting autoimmune conditions.

This study found that baricitinib, a Janus kinase inhibitor, was more effective than traditional treatments for severe alopecia areata, with higher rates of significant hair regrowth after 6 months, despite mild-to-moderate side effects and some instances of weight gain.

This study identified a new keratin, K6irs, as a potential histological marker for the inner root sheath of hair follicles in mice and humans, and as a candidate gene for hereditary hair defects.

Baricitinib is a safe and effective treatment for severe alopecia areata.

In this study, adults with severe alopecia areata experienced greater improvements in hair regrowth, health-related quality of life, and reduced anxiety and depression symptoms after 36 weeks of treatment with baricitinib compared to placebo.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

This study aims to assess the real-world effectiveness of baricitinib, a JAK inhibitor, for promoting regrowth of nasal, genital, and beard hair in patients with severe alopecia areata, expanding on findings from the BRAVE-AA clinical trial. Results are not reported.

Baricitinib stops hair loss and promotes regrowth in alopecia areata.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

This case report details a family in Iraq with biotin deficiency, highlighting improved outcomes in surviving children following diagnosis and lifelong biotin supplementation.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

This case report observed successful hair regrowth with ritlecitinib in a patient with severe alopecia who did not respond to a previous year of baricitinib therapy.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

In this study, baricitinib treatment for severe alopecia areata was well tolerated, with minor metabolic changes and PLR emerging as a sensitive marker of treatment response.

This case report presents the first known instance of bimekizumab improving psoriatic scarring alopecia, suggesting potential benefits of dual IL-17A/IL-17F blockade for this rare and challenging condition, warranting further investigation.

In this study, patients with severe alopecia areata treated with baricitinib showed continued improvement in scalp hair regrowth from weeks 52 to 152, particularly among those initially responding with eyelash or eyebrow regrowth but not scalp hair, with 39% achieving substantial regrowth by week 104.

This study found that baricitinib was effective and well tolerated for long-term scalp hair regrowth in severe alopecia areata patients, with certain predictors identified for treatment response.

This study observed significant repigmentation in localized stable vitiligo lesions treated with oral baricitinib, with even more improvement when combined with topical tacrolimus, and reported no side effects.